Pituitary deficiency of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) is a condition characterized by reduced or absent secretion of the gonadotropins by the gonadotroph cells of the anterior pituitary, resulting in the inability to sustain normal gonadal steroidogenesis and gametogenesis. Since LH and FSH represent the essential pituitary output of the hypothalamic pituitary gonadal axis, their deficiency produces a picture of hypogonadotropic hypogonadism in which reproductive impairment is accompanied, when the deficit is prolonged or occurs during critical phases of development, by systemic consequences involving bone, body composition, metabolism and psychosexual well-being.
The clinical peculiarity of this “central” form of hypogonadism is that the defect does not lie in the gonad, but in the gland that must translate the hypothalamic signal into peripherally effective hormonal secretion. This entails marked etiological heterogeneity, including structural compressive, infiltrative or vascular causes of the sellar region, iatrogenic forms and congenital pictures of altered pituitary development. In practical terms, recognizing pituitary deficiency of LH and FSH means correctly framing the problem within the context of overall pituitary function, distinguishing potentially reversible forms from permanent ones and establishing treatment that explicitly separates the restoration of sex steroid effects from the distinct objective of fertility recovery.
The frequency of pituitary deficiency of LH and FSH depends closely on the epidemiology of hypopituitarism and on the causes that selectively or predominantly affect gonadotroph function. In adulthood, a relevant proportion of hypogonadotropic hypogonadism is related to diseases of the sellar and parasellar region, with particular importance of non-secreting pituitary neoplasms, macroadenomas with mass effect, craniopharyngiomas and lesions that interfere with the perfusion or integrity of the pituitary parenchyma. In these settings, gonadotroph impairment is often among the first to emerge, because the reproductive axis is highly sensitive to reduced hypothalamic drive and to altered function of gonadotroph cells.
In women, LH and FSH deficiency may become clinically evident relatively early because of menstrual abnormalities, anovulation and infertility, whereas in men the presentation may be more subtle and prolonged, with reduced libido, decreased erectile function, asthenia and body composition changes before central hypogonadism is recognized. This difference in clinical “visibility” contributes to apparent variability in detection and epidemiological estimates, even when the underlying sellar disease is the same.
With regard to risk factors, a first crucial distinction concerns conditions that cause direct pituitary damage as opposed to those that secondarily alter hypothalamic pituitary regulation. Strictly defined “pituitary” deficiency is associated with predisposing factors such as the presence of sellar macrolesions, transsphenoidal surgery, cranial or sellar radiotherapy, pituitary apoplexy, peripartum hemorrhage or ischemia and chronic infiltrative or inflammatory processes. In these scenarios, the risk of hypogonadotropic hypogonadism increases further when signs of impairment of other axes coexist, such as central hypothyroidism or central adrenal insufficiency, which suggest more extensive pituitary damage.
An epidemiologically relevant category is post-treatment deficiency. Surgery for pituitary tumors and radiotherapy, while essential tools in the management of sellar diseases, may cause new hormonal deficiencies or worsen pre-existing deficits. Gonadotroph function may recover in a proportion of patients after surgical decompression of nonfunctioning adenomas, but it may also deteriorate permanently, requiring dynamic follow-up that is not limited to the immediate postoperative phase.
In childhood and adolescence, epidemiology is dominated by congenital forms and by the spectrum of multiple anterior pituitary deficiencies related to defects of pituitary development. Mutations in transcription factors and genes involved in pituitary organogenesis may produce a picture of combined deficiency in which gonadotroph deficiency typically emerges at the expected time of pubertal activation. In these cases, the natural history is often characterized by progression and interindividual variability, with the possibility that gonadotroph function deteriorates over time even when the initial deficits involve other axes.
Finally, some clinical settings require particular attention because they increase the likelihood of delayed diagnosis. These include slowly developing forms associated with sellar microlesions, pictures of hyperprolactinemia due to “stalk effect” that mask central hypogonadism, and presentations in which symptoms are attributed to nonspecific causes such as stress, depression or aging. In all these cases, systematic assessment of risk factors and of the sellar context is essential for correctly interpreting hypogonadotropic hypogonadism as an expression of pituitary deficiency of LH and FSH.
Pituitary deficiency of LH and FSH derives from a quantitative or qualitative alteration in the function of gonadotroph cells of the anterior pituitary, or from a functional interruption of the hypothalamic pituitary connection that prevents the gonadotropin-releasing hormone (GnRH) signal from being translated into adequate gonadotropin secretion. The etiology includes congenital, acquired and iatrogenic forms, with pathogenetic mechanisms ranging from cellular loss to secretory disorganization and reduced residual secretory reserve.
Among acquired causes, the mass effect of nonfunctioning pituitary adenomas and other sellar lesions represents a pathophysiological paradigm: compression of the normal pituitary parenchyma and distortion of the vascular architecture may reduce perfusion and functionality of gonadotroph cells. Damage may be gradual and initially selective, because different cell types show different sensitivity to compression and ischemia, but over time it may evolve toward more extensive hypopituitarism. A frequently intertwined mechanism is impairment of the pituitary stalk with reduced portal transport of hypothalamic factors, which may alter gonadotroph stimulation and simultaneously cause hyperprolactinemia through loss of dopaminergic inhibition, amplifying suppression of the reproductive axis.
Vascular causes include pituitary apoplexy and peripartum ischemia. In these conditions, the central event is an acute insult that causes necrosis or hemorrhage with loss of functioning pituitary tissue. Gonadotroph deficiency may be part of a complete or partial picture and often coexists with adrenocorticotropic hormone (ACTH) and thyroid-stimulating hormone (TSH) deficiencies, with immediate implications for clinical safety and treatment priority.
Infiltrative and inflammatory forms, such as sarcoidosis, histiocytosis, hypophysitis and other granulomatous or autoimmune diseases, produce deficiency through mechanisms of tissue infiltration, fibrosis and alteration of local homeostasis. In these scenarios, damage may be irregular and fluctuating, with phases of inflammatory activity and cicatricial progression, making the pathophysiology of gonadotropin secretion particularly variable over time.
Iatrogenic causes mainly include surgery and radiotherapy. Surgery may remove pathological tissue but may also compromise healthy tissue, whereas radiotherapy tends to cause progressive hormonal deterioration over time, with the appearance of new deficits even years later. Post-irradiation pathophysiology reflects microvascular damage, fibrosis and gradual loss of secretory capacity, making long-term follow-up necessary rather than surveillance limited to the immediate post-treatment phase.
In congenital forms, LH and FSH deficiency may result from defects of pituitary development related to mutations in genes involved in organogenesis and differentiation of the different cellular lineages. In this case, the mechanism is often a reduced functional mass of gonadotroph cells or their secretory incompetence, and the clinical presentation typically emerges at puberty, when the body requires a coordinated increase in gonadotropin production. A distinctive element of many genetic forms of hypopituitarism is possible progression, with the appearance of new deficits over time even if the clinical onset initially involves only one axis.
From a pathophysiological perspective, reduced LH and FSH result in insufficient gonadal stimulation. In men, this causes reduced testosterone production and impaired spermatogenesis, because LH supports Leydig cell function and FSH acts on Sertoli cells, with effects on seminiferous tubule maturation, inhibin B production and support of gametogenesis. In women, FSH deficiency and the absence of an adequate LH signal cause arrest of follicular growth, low estradiol levels, absence of ovulation and inadequate luteinization, with consequent infertility and amenorrhea.
Chronic deficiency of sex steroids has systemic effects that are an integral part of clinical pathophysiology. Reduced estrogenic or androgenic exposure impairs maintenance of bone mass, alters body composition by favoring increased fat mass and reduced lean mass, and modifies metabolic parameters with a tendency toward worsening insulin sensitivity and lipid profile. In addition, the reproductive axis interacts with neuroendocrine circuits involved in behavior and well-being, so prolonged gonadotroph deficiency may present with reduced vitality, mood changes and sexual dysfunction. In summary, pituitary deficiency of LH and FSH is not merely a fertility disorder, but a condition that globally alters the physiology of reproductive adaptation and its systemic effects.
The clinical presentation of pituitary deficiency of LH and FSH depends decisively on the age at onset and the speed with which the deficit develops, as well as on the presence of associated pituitary deficiencies and the underlying cause. Assessment must follow the logic of a real clinical examination, starting from targeted history taking and then moving to objective findings that make the clinical suspicion coherent with the expected endocrine pattern.
On history taking, in children and adolescents the guiding element is delayed puberty or complete absence of pubertal signs. In males, failure of testicular volume to increase is often the earliest and most specific sign, because it directly reflects the absence of gonadotropin stimulation; poor virilization, reduced development of muscle mass and failure of androgen-dependent hair development may coexist. In females, absence of thelarche or failure of breast development to progress, primary amenorrhea and absence of signs of pubertal maturation point toward a central defect, especially when there are no elements of primary ovarian insufficiency. At this stage of life, history taking must include information on linear growth, headache, visual disturbances and symptoms of other pituitary deficiencies, because isolated gonadotroph deficiency is less common than more complex pictures.
In adults, history in males frequently includes reduced libido, erectile dysfunction, decreased frequency of morning erections, asthenia, reduced physical performance and possible infertility. In slowly developing onset, symptoms may be attributed to stress or aging, whereas in more rapid onsets, such as after apoplexy or sellar surgery, the appearance of hypogonadism may be more evident and associated with other signs of hypopituitarism. In women, the clinical history is often dominated by oligomenorrhea or secondary amenorrhea, anovulation, infertility and symptoms of hypoestrogenism such as vaginal dryness and dyspareunia; vasomotor symptoms and sleep disturbances may appear, especially if the estrogen fall is relatively rapid.
Physical examination must assess signs of steroid deficiency and systemic consequences. In males, there may be reduced secondary sexual characteristics, reduced muscle mass, increased adipose tissue, reduced beard growth and, in long-standing cases, reduced testicular volume. In females, signs of hypoestrogenism may be observed, with reduced mucosal trophism and reduced breast tension. In both sexes, a clinically important element is assessment of bone and muscle status, because chronic central hypogonadism increases the risk of osteopenia and osteoporosis and contributes to functional frailty.
A separate clinical chapter concerns signs of sellar mass and symptoms of other pituitary deficiencies. Headache, reduced visual field, diplopia or signs of optic chiasm compression should suggest an expansive lesion. Symptoms such as hypotension, marked asthenia, hyponatremia, cold intolerance, unexplained weight gain or polyuria and polydipsia suggest that gonadotroph deficiency is not isolated. Clinical assessment must therefore always consider LH and FSH deficiency as a possible part of a broader picture of hypopituitarism, especially when onset occurs in adulthood and the history includes sellar risk factors.
Finally, the psychosexual and reproductive dimension is an integral part of the clinical picture. Gonadotroph deficiency may impair perceived sexual identity, relationship quality, fertility and family planning. In young patients with delayed puberty, the psychological impact may be particularly relevant, whereas in adults quality of life may be affected mainly by sexual dysfunction and loss of global well-being. Integrating these aspects into clinical assessment is essential for establishing a realistic diagnostic and therapeutic pathway centered on the patient’s goals.
Suspicion of pituitary deficiency of LH and FSH arises from recognizing a discrepancy between what would be expected for the patient’s phase of life and what the reproductive axis is actually expressing. In practice, the clinical question is whether puberty, ovarian cyclicity, sexual function and fertility are coherent with age, biological context and general status, and whether hypogonadism is more plausibly “central” rather than gonadal.
In adolescence, suspicion should arise when initial signs of puberty do not appear within the upper limits of normal for sex and age, or when a puberty that has begun stops early without progression. Failure of testicular volume to increase in males and absence of thelarche in females are clinical signals that, if associated with linear growth not necessarily impaired and absence of chronic systemic illness, require assessment of the hypothalamic pituitary gonadal axis. Suspicion is further strengthened if elements suggesting a broader pituitary defect coexist, such as a history of neonatal hypoglycemia, prolonged jaundice, micropenis or cryptorchidism, or clinical signs of other pituitary deficiencies.
In adults, pituitary deficiency of LH and FSH should be considered in the presence of symptoms of hypogonadism with reduced sex steroids and gonadotropins that are not adequately increased. Suspicion is particularly strong when sellar risk factors are present, such as a history of pituitary adenoma, surgery or radiotherapy, head trauma, meningitis, infiltrative diseases, or mass symptoms such as headache and visual disturbances. In this context, the appearance of hypogonadism together with central hypothyroidism or central adrenal insufficiency is a clinical signal that clearly points toward hypopituitarism.
Associated hyperprolactinemia is often a decisive element. In the presence of elevated prolactin and signs of hypogonadism, axis suppression may be partly mediated by the effect of prolactin on GnRH drive, but hyperprolactinemia itself may indicate compression of the pituitary stalk. In these cases, suspicion of pituitary deficiency of LH and FSH is not based only on prolactin, but on the coherent combination of history, clinical signs and the possibility of underlying sellar disease.
It is essential to distinguish suspected pituitary deficiency from functional hypothalamic forms. To do this, the clinical context must be integrated: major weight loss, excessive physical exercise, energy stress or eating disorders point toward hypothalamic suppression, whereas signs of sellar mass, the presence of multiple deficiencies and a history of surgery or irradiation point toward a pituitary defect. This distinction is not theoretical, because it affects diagnostic strategies and, above all, the therapeutic choice when fertility is the goal.
In summary, pituitary deficiency of LH and FSH should be suspected when reproductive function is inadequate for the patient’s phase of life and biological context, especially if sellar risk factors or elements of broader hypopituitarism coexist. Suspicion represents the point at which clinical assessment becomes a structured diagnostic pathway oriented toward the cause.
The diagnosis of pituitary deficiency of LH and FSH requires a sequential pathway that demonstrates hypogonadotropic hypogonadism, defines the most likely site within the hypothalamic pituitary gonadal axis and identifies the underlying cause, with particular attention to the possibility of associated hypopituitarism that may be dangerous if unrecognized, such as central adrenal insufficiency. Diagnostic logic cannot be based on a single value, but must integrate biochemistry, clinical findings and imaging.
The first level consists of basal measurement of sex steroids and gonadotropins. In men, the combination of reduced testosterone with low or inappropriately normal LH and FSH identifies the pattern of hypogonadotropic hypogonadism; in women, low estradiol associated with non-elevated gonadotropins, in the presence of amenorrhea or anovulation, suggests a central defect. At this stage, it is useful to add markers of gonadal function and germinal compartment activity, such as inhibin B in men and, in selected contexts, anti-Müllerian hormone (AMH) in women, not as decisive diagnostic tests, but as elements that help describe the phenotype and estimate residual functional reserve.
The second step is to distinguish between a hypothalamic defect and a pituitary defect. Dynamic tests with GnRH or analogues may show a preserved gonadotropin response in some hypothalamic forms, but their clinical usefulness is limited by protocol variability, overlap in responses and the fact that most management decisions still depend on identifying the sellar cause and assessing the other axes. In practice, differentiation is based mainly on the clinical context, the presence of multiple deficiencies and sellar imaging. A strongly orienting finding for pituitary impairment is the coexistence of deficiencies of other pituitary hormones or the presence of a sellar lesion involving the pituitary parenchyma.
Assessment of overall pituitary function is indispensable. Depending on context and clinical priority, cortisol and ACTH must be measured, with dynamic tests when indicated, together with thyroid hormones with TSH interpreted in a central framework, insulin-like growth factor 1 (IGF-1) as a marker of the growth hormone (GH) axis, and prolactin. This step is not accessory because a gonadotroph deficit may be the most evident element, but not the most urgent one from the standpoint of clinical safety. Correct diagnosis therefore includes definition of the overall hypopituitarism profile and not only of the gonadal axis.
The reference imaging modality is magnetic resonance imaging of the hypothalamic pituitary region with study of the sella and optic chiasm. The aim is to identify adenomas, craniopharyngiomas, hypophysitis, infiltrations, ischemic sequelae, empty sella and abnormalities of the stalk. Even in the presence of nonconclusive imaging, pituitary deficiency may be present in post-treatment sequelae or microstructural forms, but documented imaging remains central for anatomical staging and therapeutic decisions.
According to the Endocrine Society recommendations on adult hypopituitarism, to frame gonadotroph deficiency in suspected hypopituitarism it is necessary to
Once the picture of hypogonadotropic hypogonadism has been defined and the sellar site or pituitary context documented, the diagnosis is completed by identifying the etiology. In the presence of a pituitary tumor, it is necessary to distinguish functioning from nonfunctioning adenomas, understand whether prolactin plays a role and establish the relationship with visual disturbances. In inflammatory or infiltrative pictures, integration with systemic tests and, when appropriate, extended immunological and radiological assessments is essential. In congenital or early-onset forms with multiple hypopituitarism or malformations, genetic investigation and neuroradiological evaluation of the pituitary hypothalamic complex can better define the diagnosis and guide family counseling.
The differential diagnosis primarily includes primary gonadal hypogonadism, which is characterized by elevated gonadotropins, but also conditions that transiently alter testosterone or estradiol, the use of medicines that suppress the axis, and functional hypothalamic forms. In the latter case, the absence of a sellar lesion and the presence of clear metabolic or behavioral precipitating factors point toward a hypothalamic defect, whereas coexistence of other deficiencies and pathological imaging make pituitary deficiency more likely. The final objective of the diagnostic workup is not merely to “label” central hypogonadism, but to insert it into a pathophysiological map that allows treatment, follow-up and reproductive objectives to be established with clinical coherence.
The classification of pituitary deficiency of LH and FSH is useful above all because it connects the clinical phenotype with natural history and therapeutic strategy. A first distinction is between isolated deficiency and deficiency associated with other pituitary deficits. Isolated deficiency is relatively less frequent in acquired sellar diseases, whereas it may occur in some specific conditions or in the early phases of a compressive process. Conversely, the presence of central hypothyroidism, central adrenal insufficiency or GH deficiency suggests broader damage and requires integrated management.
A second classification axis distinguishes congenital and acquired forms. Congenital forms include both pictures of altered pituitary development with multiple deficiencies and more circumscribed forms in which the gonadotroph component is particularly clinically expressive. In these forms, severity must be interpreted in relation to the moment when the body requires adequate gonadotropin output, especially during puberty, and to the possibility that function deteriorates over time.
Acquired forms include neoplastic, vascular, inflammatory, infiltrative and iatrogenic diseases. In this category, severity is often linked to lesion size, degree of compression and duration of damage. A slowly developing deficit may allow partial adaptations and present with subtle symptoms, whereas an acute event may cause a sudden fall in gonadal function and a more evident clinical picture.
It is also useful to distinguish between partial and complete deficiency. In partial deficiency, residual gonadotropin secretion may persist, sometimes sufficient to support some aspects of gonadal function, with incomplete puberty or irregular cycles in women and reduced but not always absent fertility in men. In complete deficiency, the absence of gonadotropin stimulation markedly prevents gametogenesis and steroidogenesis, with pictures of persistent amenorrhea, azoospermia or reduced testicular volume in cases with early onset. The distinction is clinically relevant because it affects the probability of response to fertility treatments and the choice of protocols.
A further criterion, especially in post-treatment or tumor forms, is the possibility of recovery of gonadotroph function. After surgical decompression of nonfunctioning adenomas, a proportion of patients may show partial recovery of the gonadal axis, whereas others may develop new deficiencies. This variability makes classification intrinsically dynamic and justifies structured follow-up over time, in which severity is not “established once and for all”, but reassessed according to clinical response, biochemistry and neuroradiological context.
Finally, severity must always be reinterpreted in light of clinical goals. A gonadotroph deficit may be “clinically mild” if the patient has no relevant symptoms and does not desire fertility, but may become “clinically crucial” if the objective is induction of physiological puberty, achievement of fertility or prevention of bone and metabolic complications in a young subject. For this reason, classification must be used as a decision-making tool rather than as a simple descriptive label.
Treatment of pituitary deficiency of LH and FSH must clearly separate two objectives that are often confused: the restoration of sex steroid effects and the recovery of fertility. Replacement therapy with testosterone or estrogens and progestins may normalize symptoms and prevent systemic complications, but it does not induce gametogenesis and does not replace the gonadotropin stimulation required to produce spermatozoa or ovulation. The therapeutic choice must therefore be individualized according to age, sex, reproductive desire, comorbidities and the cause of the deficiency.
In adolescents with pubertal-onset deficiency, treatment aims to induce progressive sexual development consistent with physiology. In males, testosterone is used at gradually increasing doses to mimic the pubertal rise and avoid excessively rapid skeletal maturation. In females, estrogen therapy is started at increasing doses, followed by introduction of a progestin to ensure endometrial protection when appropriate. Gradual progression is essential not only for metabolic and bone safety, but also for psychological adaptation and to achieve harmonious development of secondary sexual characteristics.
In adults who do not desire fertility, treatment consists of steroid replacement aimed at correcting symptoms, preserving bone and muscle mass and improving quality of life. In men, testosterone therapy requires choice of formulation and appropriate monitoring, including clinical assessment, hematocrit and prostate safety according to the relevant recommendations. In women of reproductive age with central hypoestrogenism, estrogen progestin therapy aims to restore trophism and protect bone and the cardiovascular system, taking into account the individual risk profile. After menopause, the indication is more selective and depends on symptoms and bone health objectives, with decisions that must be contextualized.
When fertility is the objective, pituitary deficiency generally requires exogenous gonadotropins because pulsatile GnRH administration, although physiological in hypothalamic forms, is ineffective or poorly effective if the pituitary is unable to respond. In men, induction of spermatogenesis is based on human chorionic gonadotropin (hCG) as a functional substitute for LH action on Leydig cells, often associated with recombinant FSH or menotropins to stimulate Sertoli cells and support maturation of the seminiferous tubules. The response is slow and requires months, because spermatogenesis has irreducible biological timing and because in prepubertal-onset deficiencies testicular maturation may be reduced, making prolonged and adapted stimulation strategies necessary.
In women with gonadotroph deficiency, fertility treatment is based on controlled ovarian stimulation with FSH and, in cases of profound LH deficiency, on the addition of recombinant LH or on the use of preparations containing LH activity. The objective is to obtain follicular growth, adequate estradiol increase, oocyte maturation and ovulation, while avoiding hyperstimulation. Management requires accurate ultrasound and hormonal monitoring, because ovarian sensitivity and response to doses vary widely, and the risk of excessive response or ineffective cycles depends on protocols and phenotype.
In parallel, treatment must address the cause when possible. In nonfunctioning macroadenomas, surgical decompression may improve pituitary function in some patients, including gonadotroph function, but may also cause new deficiencies, so the therapeutic decision must balance neuro-ophthalmological and endocrine benefits against the risk of functional worsening. In inflammatory pictures, treatment of the underlying disease may stabilize or improve function. In post-radiotherapy cases, the approach is often substitutive and long term, with adjustments according to clinical evolution.
In all patients, treatment optimization requires that replacement of the other pituitary axes be correct and safe. A patient with inadequately treated central adrenal insufficiency may not tolerate interventions or reproductive therapies and may have increased clinical risk. For this reason, treatment of gonadotroph deficiency must be inserted into an overall strategy for management of hypopituitarism, rather than considered an isolated intervention.
Follow-up of pituitary deficiency of LH and FSH must be structured because pituitary function can change over time in relation to growth of sellar lesions, late effects of radiotherapy, evolution of infiltrative diseases or partial recovery after surgical decompression. Monitoring is not limited to assessment of symptomatic response, but includes safety of replacement therapy, surveillance of systemic complications and periodic reassessment of overall pituitary function.
In patients of developmental age, follow-up must monitor induced pubertal progression, linear growth and bone maturation, with attention to a coherent and harmonious developmental rhythm. It is necessary to periodically assess development of secondary sexual characteristics and, when clinically indicated, biochemical parameters reflecting steroid exposure. The objective is to avoid both insufficient therapy, which leaves bone and psychosocial risks persistent, and excessive therapy, which may accelerate bone maturation and reduce residual growth potential.
In adults, follow-up of steroid therapy is based on clinical assessment of symptoms, safety parameters and prevention of complications. In men receiving testosterone therapy, monitoring includes hematocrit and assessment of adverse events, in addition to clinical control of response. In women receiving estrogen progestin therapy, surveillance is oriented toward tolerability, thromboembolic risk in the presence of predisposing factors and control of hypoestrogenism symptoms, with choices that must be updated over time as the risk profile and phase of life change.
A central axis of follow-up is bone health. In the presence of prolonged central hypogonadism, assessment of bone mineral density and fracture risk must be integrated into monitoring, especially in patients with delayed diagnosis, long duration of deficiency or coexistence of other risk factors. Prevention of bone loss depends not only on steroid therapy, but also on nutritional status, vitamin D, adequate physical activity and control of any other concomitant endocrine deficiencies.
In patients with reproductive desire, follow-up is more intensive and depends on the protocol. In men undergoing induction of spermatogenesis with gonadotropins, monitoring must include assessment of testicular response, testosterone levels and serial semen analyses according to appropriate biological timing. In women undergoing ovarian stimulation, follow-up requires ultrasound examinations and hormone measurements to modulate therapy, prevent hyperstimulation and optimize the chances of ovulation and pregnancy. In both sexes, integration with reproductive medicine is essential when the response is suboptimal or when assisted reproductive technologies become necessary.
Since gonadotroph deficiency may coexist with other pituitary deficiencies, follow-up must include periodic reassessment of cortisol, central thyroid function and, when appropriate, the GH axis and prolactin. After surgery or radiotherapy, pituitary function may change in either an improving or worsening direction, making prolonged surveillance necessary. In addition, sellar imaging must be repeated according to neuroradiological and clinical indications related to the underlying disease, to monitor stability or progression of the lesion and correctly interpret any endocrine changes.
Finally, follow-up must include the dimension of quality of life and psychosexual well-being. Symptomatic response does not always coincide with biochemical normalization, and technically correct therapy may not meet the patient’s personal or reproductive goals. Periodically reassessing goals, expectations and functional impact allows management to be adapted over time and keeps treatment aligned with pathophysiology and real needs.
The prognosis of pituitary deficiency of LH and FSH is generally favorable for life expectancy when the sellar cause is recognized and when associated hypopituitarism is treated appropriately, especially with regard to vital axes. However, functional outcome depends on age at onset, duration of untreated deficiency, presence of multiple deficiencies and possibility of recovery of pituitary function after etiological treatment. A deficit that develops before or during puberty, if unmanaged, may cause deeper consequences for somatic and bone development than a deficit that arises in adulthood.
A central complication is impairment of skeletal health. Chronic sex steroid deficiency reduces acquisition of peak bone mass in young people and accelerates bone loss in adults, increasing the risk of osteopenia, osteoporosis and fractures. This complication is particularly relevant in patients with delayed diagnosis and in settings in which replacement therapy is insufficient or discontinuous. The pathophysiology is consistent with the role of estrogens and androgens in maintaining bone remodeling, controlling osteoclast activity and preserving microarchitecture.
Metabolically, prolonged central hypogonadism contributes to changes in body composition with increased fat mass and reduced lean mass, with possible worsening of insulin sensitivity and lipid profile. These effects may add to those of other pituitary deficiencies and replacement therapies, making global assessment of cardiometabolic risk and targeted lifestyle interventions necessary.
Reproductive complications include infertility and, in women, persistent anovulation. Reproductive prognosis is often good with appropriate therapies, but the response depends on factors such as duration of the deficit, previous gonadal maturation and presence of comorbidities. In men with prepubertal-onset deficiency, induction of spermatogenesis may require longer times and may be less predictable, whereas in women with profound LH deficiency specific support with LH activity may be needed to obtain effective folliculogenesis.
A further area of complications concerns quality of life and psychosexual well-being. Reduced libido, sexual dysfunction, mood changes and perceived reduced vitality are frequent and may persist even with replacement therapy if not addressed in an integrated manner. In young patients, delayed puberty may have significant psychological impacts, with effects on self-esteem and social life, making support that accompanies endocrine therapy important.
Prognosis also depends on the underlying cause. In nonfunctioning pituitary tumors, gonadotroph function may recover in a proportion of patients after surgery, but it may also worsen or deteriorate over time, especially after radiotherapy. In peripartum ischemia, the endocrine prognosis may be persistent multiaxis deficiency, whereas in inflammatory forms the course may be variable. For this reason, prognosis must be formulated not as a static judgment, but as a synthesis of individual pathophysiology, expected recovery profile and the quality of long-term follow-up and treatment.